Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01218867
Title Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

colorectal cancer

kidney cancer

ovarian cancer

lung cancer

Advanced Solid Tumor

melanoma

Therapies

Anti-VEGFR2 CAR CD8 lymphocytes

Cyclophosphamide

Fludarabine

Aldesleukin

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.